Biotech Values

[jq1234]

I agree ph2 trial had bias toward placebo arm. That to me along with crossover provided important margin of error. As of including mEGFR, the trial population is based on histology non-squamous, you really can't further slice and dice it by excluding molecular type where erlotinib works really well. That's called bias. OS for wtEGFR is key secondary endpoint.